Results 31 to 40 of about 519,893 (158)

Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine

International Journal of Infectious Diseases, 2022
Background: Health care workers (HCWs), a high-risk group for contracting COVID-19 disease, are being prioritized to receive COVID-19 vaccination. A third dose messenger RNA (mRNA) vaccine, mRNA-1273 (Moderna), after 2 doses of inactivated vaccine ...
Cucunawangsih Cucunawangsih, Ratna Sari Wijaya, Nata Pratama Hardjo Lugito, Ivet Suriapranata   +3 more
doaj   +1 more source

mRNA-1273 elicits higher NAb responses in treatment-naïve CLL vaccinees.

, 2023
(A) ID50 neutralizing titers against the SARS-CoV-2 D614G and Delta variants in all CLL patients who received either the BNT162b2 or the mRNA-1273 vaccine.
Kai Qin (293713), Anju Bansal (56201), Randall S. Davis (8450517), Weimin Liu (50340), Sarah Sterrett (161415), Kazuhito Honjo (8450493), Victor M. Cruz Portillo (16469335), Benjamin M. Larimer (14928039), Mayur Narkhede (3826087), Regina M. Stoltz (16469317), Jeffrey R. Lancaster (1932982), Foluso J. Ogunsile (16469329), Paul A. Goepfert (7181315), Ellen R. Frederick (16469326), Allisa K. Oman (16469320), Rima B. Patel (16469332), Lucinda A. Hall (16469323), Ran Li (57928), Amitkumar Mehta (800257), Beatrice H. Hahn (8157399), Thomas J. Ketas (460721), Scott Sherrill-Mix (692150), Albert Cupo (409522)   +22 more
core   +1 more source

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021

Journal of the Formosan Medical Association, 2022
Background: Whether immunocompromising conditions affect the immunogenicity of COVID-19 booster vaccination remains a concern, which impedes the vaccination campaign in people most vulnerable to COVID-19-associated morbidity and mortality.
Kuan-Yin Lin, Ming-Ju Hsieh, Sui-Yuan Chang, Si-Man Ieong, Chien-Yu Cheng, Wang-Huei Sheng, Shan-Chwen Chang   +6 more
doaj   +1 more source

Flow chart for 2-dose mRNA-1273 analysis cohort.

, 2022
Flow chart for 2-dose mRNA-1273 analysis cohort.
Katia J. Bruxvoort (12476079), Yun Tian (411157), Hung Fu Tseng (12476097), Ana Florea (12476073), Gina S. Lee (12476085), Jennifer H. Ku (12476088), Yi Luo (143206), Lei Qian (292302), Bradley K. Ackerson (12476082), Julia E. Tubert (12476091), Lina S. Sy (12476076), Carla A. Talarico (12476094)   +11 more
core   +1 more source

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent SARS-CoV-2 infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking.
Trkola, A., Eichenberger, Anna L, Günthard, Huldrych F, Speich, Benjamin, Audigé, A., Chammartin, Frédérique, Mueller, N.J., Koller, Michael T, Tamm, M., Schuurmans, Macé M, Stoeckle, M.P., Trkola, Alexandra, Amico, P., Audigé, Annette, Rauch, A., Bucher, Heiner C, Chammartin, F., Abela, I.A., Braun, Dominique L, Mueller, Nicolas J, Swiss HIV Cohort Study, Swiss Transplant Cohort Study, Amico, Patrizia, Speich, B., Hasse, Barbara, Koller, M.T., Kusejko, K., Tamm, Michael, Rauch, Andri, Müller, Thomas F, Braun, D.L., Briel, M., Günthard, H.F., Schuurmans, M.M., Stoeckle, Marcel P, Kusejko, Katharina, Hasse, B., Briel, Matthias, Bucher, H.C., Müller, T.F., Eichenberger, A.L., Abela, Irene A   +41 more
core   +3 more sources

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines

Microbiology Spectrum, 2021
Studies examining antibody responses by vaccine brand are lacking and may be informative for optimizing vaccine selection, dosage, and regimens. The purpose of this study is to assess IgG antibody responses following immunization with BNT162b2 (30 μg ...
José G. Montoya, Amy E. Adams, Valérie Bonetti, Sien Deng, Nan A. Link, Suzanne Pertsch, Kjerstie Olson, Martina Li, Ellis C. Dillon, Dominick L. Frosch   +9 more
doaj   +1 more source

Durable Anti-SARS-CoV-2 Antibody Response after mRNA-1273 Booster in Peritoneal Dialysis Patients during the Omicron Wave

, 2023
Anti-SARS-CoV-2 vaccination of dialysis patients has been proven to be safe and effective to reduce COVID-19-related morbidity and mortality. However, data on the durability of anti-SARS-CoV-2 antibodies post-vaccination in peritoneal dialysis (PD ...
Robert Strassl, Andreas Vychytil, Florian Frommlet, Roman Reindl-Schwaighofer, Georg Beilhack, Rossella Monteforte   +5 more
core   +1 more source

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

, 2023
The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed.
Musk, Elon R, Cizmeci, Deniz, Collier, Ai-ris, Krammer, Florian, Dayal, Diana, Amanat, Fatima, Suscovich, Todd, Mann, Colin, Menon, Anil S, Kaplonek, Paulina, Nilles, Eric J, Rhee, Justin, Broge, Thomas, de St Aubin, Michael, Saphire, Erica Ollmann, Barouch, Dan H, Alter, Galit, Fischinger, Stephanie, Linde, Caitlyn, Lauffenburger, Douglas A   +19 more
core   +1 more source

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age [PDF]

, 2022
BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. METHODS: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was
Chronis, Carey, McPhee, Roderick, Ramirez Schrempp, Daniela, Creech, C. Buddy, Griffin, Carl, Girard, Bethany, Garner, Fredric, Zervos, Marcus J, Nayak, Jennifer, Piramzadian, Arin, Ampajwala, Madhavi, Smith, Christopher A, Berthaud, Vladimir, Berman, Gary, Das, Rituparna, Reuter, Caroline, Slobod, Karen, Tomassini, Joanne E, Johnson, Kimball A, Zhao, Xiaoping, Bennett, Richard L, Muller, William J, Anderson, Evan J, Palanpurwala, Khozema, Aunins, Anne, Hautzinger, Kelly, Turner, Mark, Deng, Weiping, Zhou, Honghong, Rizzardi, Barbara, Pajon, Rolando, Hsia, Daniel, DeLucia, Dianne, Schnyder Ghamloush, Sabine, Ali, Kashif, Miller, Jacqueline M, Gerber, Jeffrey, Fuchs, George, Kuter, Barbara   +38 more
core   +2 more sources

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 [PDF]

, 2022
IMPORTANCE It has become common practice to offer immunocompromised patients with hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce.OBJECTIVE To assess whether a third mRNA-1273 vaccination is associated with ...
Haggenburg, S., Hartog, G. den, Haverkate, N.J.E., Bouhuijs, J.H., Beaumont, T., Hazenberg, M.D., Meerten, T. van, Cobra Kai Study Team, Hofsink, Q., Bhoekhan, M.S., Leeuwen, E.M.M. van, Broers, A.E.C., Burger, J.A., Nijhof, I.S., Kater, A.P., Rutten, C.E., Kootstra, N.A., Goorhuis, A., Wouters, D., Lissenberg-Witte, B.I., Doesum, J.A. van, Binnendijk, R.S. van, Smits, G.P., Gils, M.J. van, Groen, K., Bontkes, H.J., Mutsaers, P.G.N.J., Zweegman, S., Heemskerk, M.H.M.   +28 more
core   +4 more sources